List of Excipients in Branded Drug NIRAVAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	NIRAVAM	alprazolam	16590-938	CELLULOSE, MICROCRYSTALLINE
STAT RX USA LLC	NIRAVAM	alprazolam	16590-938	CROSPOVIDONE
STAT RX USA LLC	NIRAVAM	alprazolam	16590-938	FERRIC OXIDE YELLOW
STAT RX USA LLC	NIRAVAM	alprazolam	16590-938	MAGNESIUM STEARATE
STAT RX USA LLC	NIRAVAM	alprazolam	16590-938	MANNITOL
STAT RX USA LLC	NIRAVAM	alprazolam	16590-938	SILICON DIOXIDE
STAT RX USA LLC	NIRAVAM	alprazolam	16590-938	STARCH, CORN

Niravam Excipient Strategy and Commercial Opportunities for Alprazolam Orally Disintegrating Tablets

Last updated: July 31, 2026

Niravam is an alprazolam orally disintegrating tablet (ODT) approved in the United States for panic disorder, with or without agoraphobia. Its formulation uses a conventional fast-dissolving platform built around mannitol, gelatin, crospovidone, aspartame, flavoring and magnesium stearate.[1] The commercial opportunity is no longer a conventional branded-product play. It is concentrated in generic ODT development, excipient substitution, differentiated taste and mechanical performance, and potential 505(b)(2) products with improved usability or formulation attributes.

What is Niravam and how does its dosage form work?

Niravam contains alprazolam, a benzodiazepine and Schedule IV controlled substance. It is supplied as 0.25 mg, 0.5 mg, 1 mg and 2 mg orally disintegrating tablets.[1]

The tablet is designed to disintegrate on the tongue without water. The dosage form is relevant for patients who have difficulty swallowing conventional tablets or who need a portable dosage form. The ODT does not eliminate the pharmacologic risks associated with alprazolam, including sedation, dependence, withdrawal and respiratory-depression risks when combined with opioids or other central nervous system depressants.[1,2]

What excipients are used in Niravam?

The labeled inactive ingredients are:

Excipient	Primary formulation role
Mannitol	Bulking agent, filler, mouthfeel modifier and cooling sweetener
Gelatin	Structural matrix and tablet-forming component
Crospovidone	Superdisintegrant that promotes rapid tablet breakup
Aspartame	High-intensity sweetener and taste-masking aid
Flavoring	Improves palatability
Magnesium stearate	Lubricant used during tablet manufacture

The composition reflects the requirements of an ODT: rapid wetting, fast disintegration, acceptable mouthfeel, sufficient tablet strength and effective taste masking.

What excipient strategy is most appropriate for Niravam generic development?

A generic developer should treat the Niravam formulation as a performance target rather than as a fixed excipient recipe. The main development risks are low-dose content uniformity, alprazolam bitterness, friability, moisture sensitivity and rapid disintegration without excessive tablet erosion during packaging or handling.

How should mannitol be evaluated?

Mannitol is a strong platform excipient for alprazolam ODTs because it provides a relatively clean mouthfeel and a cooling sensation. Direct-compression grades can support simple manufacturing, while spray-dried or co-processed grades can improve flow and compactability.

Potential commercial advantages include:

• Improved tablet hardness at a low compression force
• Reduced gritty residue
• Better sensory performance than some lactose-based systems
• A familiar excipient profile for regulatory review
• Compatibility with sugar-free positioning

The main risks are brittle tablets, segregation in low-dose formulations and sensitivity to grade-specific particle-size distribution. A developer should control mannitol grade, density, moisture and particle size as critical material attributes.

Can gelatin be replaced?

Yes. Gelatin is not essential to the ODT concept, but substitution can create a meaningful product distinction.

Potential alternatives include:

• Microcrystalline cellulose
• Crospovidone-based direct-compression matrices
• Polyvinylpyrrolidone
• Low-substituted hydroxypropyl cellulose
• Hydroxypropyl cellulose
• Pullulan or other film-forming polymers
• Starch-based or co-processed excipient systems

A gelatin-free product could address vegetarian, religious, cultural and animal-origin preferences. The replacement must preserve tablet strength, disintegration time, moisture stability and mouthfeel. It also may avoid supply-chain variability associated with bovine or porcine gelatin.

The regulatory value of gelatin substitution depends on whether the change produces a distinct formulation, a different manufacturing process or a new product profile. A conventional ANDA strategy remains possible if the finished product meets applicable sameness and bioequivalence requirements. A more substantial formulation or delivery change may support a 505(b)(2) pathway, but the regulatory burden and commercial differentiation would increase.

Is aspartame a commercial weakness?

Aspartame improves sweetness at low concentration but creates a labeling limitation for patients with phenylketonuria because it contains phenylalanine.[1] Replacing it with sucralose, acesulfame potassium, saccharin sodium, steviol glycosides or a polyol blend could broaden patient acceptability.

The strongest commercial rationale is not simply “aspartame-free.” The replacement should be linked to a measurable product benefit, such as:

• Lower bitterness aftertaste
• Reduced sweetness variability
• Better stability under temperature and humidity stress
• Improved suitability for patients avoiding phenylalanine
• A more acceptable taste profile for repeated dosing

Sweetener selection should be assessed with human sensory testing. Alprazolam has a bitter taste, and sweetness alone may not provide adequate masking.

What taste-masking technologies can improve Niravam?

Taste masking is a central development opportunity because alprazolam dissolves rapidly in the oral cavity and can expose patients to bitterness before swallowing.

Which taste-masking approaches are commercially practical?

Technology	Potential benefit	Main development issue
Ion-exchange resin complex	Reduces immediate drug release in the mouth	May alter release and bioavailability
Polymer coating	Provides physical taste barrier	Coating must not delay therapeutic release
Drug-loaded microparticles	Improves sensory performance and dose uniformity	Adds process complexity
Cyclodextrin complexation	Can reduce free drug concentration in saliva	May increase excipient load and cost
Lipid or wax matrix	Masks bitterness and improves handling	Risk of delayed dissolution
Flavor and sweetener system	Low-cost formulation adjustment	Often insufficient for strongly bitter drugs

For Niravam, a low-complexity approach using a robust sweetener-flavor system may be commercially adequate if sensory testing confirms acceptability. A coated-particle or ion-exchange strategy has greater differentiation potential but introduces more critical process parameters and may complicate bioequivalence.

A taste-masked product should be evaluated for disintegration, dissolution in small-volume media, saliva-phase release and pharmacokinetics. Standard dissolution alone may not predict patient-perceived bitterness.

What formulation patents could protect an improved alprazolam ODT?

The strongest protectable subject matter would usually be a specific formulation or process with measurable performance, rather than the broad concept of an alprazolam ODT.

Potential claim categories include:

• A defined alprazolam-to-mannitol ratio
• A gelatin-free ODT composition
• A specific taste-masked alprazolam particle
• A particular crospovidone or co-processed excipient system
• A tablet with defined disintegration and friability limits
• A moisture-protective package and tablet combination
• A manufacturing process that improves content uniformity
• A formulation with a defined saliva dissolution profile
• A combination of sweeteners and flavors producing a specified sensory result

Any patent strategy would need to address prior art surrounding alprazolam tablets, fast-dissolving dosage forms, orally disintegrating tablets and taste-masking technologies. Broad composition claims are likely to face substantial prior-art pressure. Narrow claims tied to quantitative ranges, particle engineering, performance data or a manufacturing advantage are more defensible.

When does Niravam lose exclusivity and what is the generic opportunity?

Niravam was approved by the FDA in 2006 under NDA 021434.[3] Its original regulatory and patent exclusivity period has long expired. The product therefore presents an established-product opportunity rather than an emerging-asset opportunity.

The commercial path depends on the target product:

Product strategy	Likely regulatory route	Commercial rationale
Conventional alprazolam ODT	ANDA	Lowest regulatory risk if reference-product requirements can be met
Gelatin-free or aspartame-free ODT	ANDA or 505(b)(2), depending on differences	Patient-segment differentiation
Enhanced taste-masked ODT	505(b)(2) or ANDA depending on formulation and claims	Higher development cost with stronger brand positioning
New strength or dosage form	505(b)(2)	Extends convenience or dosing flexibility
Abuse-deterrent alprazolam formulation	505(b)(2)	Differentiation, but high clinical and regulatory burden
Sublingual or buccal alprazolam product	505(b)(2)	Potentially distinct onset or administration profile

An ANDA developer would need to establish pharmaceutical equivalence and bioequivalence to the applicable reference product, along with conformity to the FDA’s requirements for orally disintegrating tablets. The existence of an approved reference product does not guarantee current commercial supply, procurement access or a simple development program.

What is the FDA and Orange Book status of Niravam?

Niravam was approved as an immediate-release alprazolam ODT. FDA labeling identifies alprazolam as the active ingredient and lists the six inactive ingredients described above.[1,3]

The Orange Book is the relevant source for current patent and exclusivity listings, therapeutic-equivalence evaluations and discontinued-product status.[4] Niravam’s commercial significance should be assessed separately from the broader alprazolam market, which includes conventional tablets, orally disintegrating tablets and other generic presentations.

Because Niravam is an older product, the principal regulatory issues are:

• Whether a current marketed reference product is available
• Whether the product is listed as discontinued or withdrawn for reasons other than safety or effectiveness
• Whether FDA identifies a reference standard for ANDA development
• Whether any current patents or exclusivity entries remain listed
• Whether the proposed formulation can match the reference product’s dosage-form characteristics

What Paragraph IV challenges or litigation affect Niravam?

No current high-value Paragraph IV campaign is generally associated with the original Niravam brand. The relevant IP risk is more likely to arise from later generic products, formulation patents or competing 505(b)(2) applications.

A prospective applicant should screen:

• FDA Orange Book listings for the relevant alprazolam ODT reference product
• FDA Paragraph IV certification notices
• District court and Federal Circuit litigation involving alprazolam ODT formulations
• Patent families covering taste masking, rapid disintegration and controlled-release alprazolam
• Regulatory exclusivity associated with any later reformulated product

For a conventional alprazolam ODT, freedom-to-operate risk is likely to center on formulation and process patents rather than the expired core active-ingredient patent estate. Litigation exposure would increase if the product makes explicit claims about a proprietary taste-masking system, rapid onset, abuse deterrence or a particular delivery profile.

How strong is the patent estate for an improved Niravam formulation?

The legacy Niravam commercial position is weak from an exclusivity perspective because the product is old and the core approval does not provide a current barrier to generic competition. A new formulation could create a stronger but narrower patent estate.

Patent strength would improve when the product has:

1. A defined excipient architecture that is difficult to design around.
2. A measurable sensory or dissolution advantage.
3. A manufacturing step that produces an unexpected technical effect.
4. Clinical or pharmacokinetic evidence supporting a meaningful product benefit.
5. Claims covering the formulation, process and package rather than only one composition.

A patent limited to a common sweetener, standard mannitol grade or routine superdisintegrant selection would generally provide limited exclusionary value. A formulation that solves alprazolam’s bitterness while retaining rapid disintegration and bioequivalence offers a more credible commercial and patent position.

What commercial opportunities exist for Niravam excipients?

Which markets are most attractive?

The most practical opportunities are:

• Generic alprazolam ODT supply
• Private-label ODT products
• Gelatin-free and aspartame-free versions
• Senior-care and swallowing-difficulty markets
• Products distributed through specialty pharmacies
• Contract development and manufacturing of low-dose ODTs
• Excipient platforms that can be reused for other bitter, low-dose CNS drugs

The reusable-platform opportunity may be more valuable than alprazolam alone. A validated mannitol-crospovidone taste-masking system could support ODT products containing other benzodiazepines, antiemetics, antipsychotics or migraine medicines.

How large is the revenue exposure?

The revenue opportunity is constrained by generic alprazolam pricing, controlled-substance compliance and competition from conventional tablets. A formulation premium would require a clear benefit in palatability, convenience, supply reliability or patient adherence.

Potential value drivers include:

• Low-cost manufacturing through direct compression
• Reduced packaging failures
• Reliable dose uniformity at 0.25 mg
• Differentiated flavor and sensory performance
• Reduced dependence on animal-derived excipients
• Institutional purchasing contracts
• A 505(b)(2) product with a clinically supported administration advantage

The product should not be positioned as a broad replacement for conventional alprazolam tablets. Its stronger niche is convenience and administration without water.

What manufacturing and IP barriers apply to alprazolam ODTs?

The main manufacturing barriers are technical rather than raw-material scarcity.

Critical process areas include:

• Uniform distribution of a low-dose active ingredient
• Control of blend segregation
• Tablet compression without capping or lamination
• Rapid disintegration at adequate hardness
• Moisture control during manufacture and packaging
• Flavor uniformity
• Prevention of cross-contamination in controlled-substance facilities
• Packaging that protects fragile tablets

Alprazolam also creates operational requirements because it is a controlled substance. Manufacturers need appropriate inventory controls, reconciliation, security and regulatory compliance. These requirements can reduce the number of qualified suppliers and create a barrier to rapid market entry.

Blister packaging may provide better unit-dose protection and portability than bottles, but it increases packaging cost. A moisture-barrier blister may be necessary if the selected excipient matrix is hygroscopic or mechanically fragile.

How does Niravam compare with conventional alprazolam tablets?

Attribute	Niravam-type ODT	Conventional alprazolam tablet
Administration	Can be taken without water	Usually swallowed with water
Patient convenience	Higher for swallowing difficulty and portability	Familiar and low cost
Manufacturing complexity	Higher	Lower
Packaging sensitivity	Often higher	Usually lower
Taste exposure	Important development issue	Less important
Generic competition	Smaller specialized segment	Broad and price competitive
Excipient differentiation	Significant	More limited
Commercial premium	Possible if usability improves	Usually limited

Key Takeaways

• Niravam is an alprazolam orally disintegrating tablet approved in 2006 under NDA 021434.
• Its labeled excipients are mannitol, gelatin, crospovidone, aspartame, flavoring and magnesium stearate.
• The most important formulation issues are bitterness, low-dose content uniformity, tablet strength, moisture stability and rapid disintegration.
• Gelatin-free and aspartame-free versions offer the clearest excipient-led differentiation.
• Conventional generic competition would generally favor an ANDA strategy, subject to current reference-product and Orange Book requirements.
• A taste-masked, clinically differentiated or novel-delivery product could support a 505(b)(2) strategy.
• The strongest patent opportunities involve defined excipient ratios, particle engineering, sensory performance, manufacturing controls and package protection.
• Controlled-substance handling and ODT manufacturing capability are practical barriers to entry.
• The broader commercial value may lie in a reusable fast-dissolving platform for other bitter, low-dose CNS drugs.

FAQs

Is Niravam the same as generic alprazolam?

Niravam is a brand formulation of alprazolam in an orally disintegrating tablet. Generic alprazolam products may use conventional tablets or different ODT formulations and are not automatically identical in excipient composition.

Can a generic Niravam omit gelatin?

A developer can pursue a gelatin-free formulation, but it must demonstrate acceptable pharmaceutical performance, stability, manufacturing quality and bioequivalence under the applicable FDA pathway.

Why is mannitol preferred in alprazolam ODTs?

Mannitol supports tablet bulk, rapid dissolution and a cooling mouthfeel. It also works well in sugar-free formulations, although its grade and particle characteristics affect compression and content uniformity.

Does an aspartame-free alprazolam ODT have a strong market advantage?

It can appeal to patients who avoid phenylalanine or prefer alternative sweeteners. The advantage is strongest when supported by better taste, equivalent stability and reliable tablet performance.

Can an alprazolam ODT claim faster onset than a conventional tablet?

An ODT may improve administration convenience and disintegration in the mouth, but a faster clinical onset claim requires appropriate pharmacokinetic and clinical evidence. Oral disintegration alone does not establish faster systemic exposure.

References

1. DailyMed. (n.d.). Niravam: Alprazolam orally disintegrating tablet prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2020). FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class.
3. U.S. Food and Drug Administration. (2006). Drugs@FDA: Niravam, NDA 021434.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.